L04AC03 - Anakinra |
Propably not porphyrinogenic |
PNP |
Important Information
Patients on immunosuppressive therapy have an increased risk of infections. Since infections have a potential to trigger acute porphyric attacks vigilance is motivated regarding signs or symptoms of infection and/or possible symptoms of a porphyric attack.
Side effects
Infections are common in patients using immunosuppressants and since infections might trigger an acute porphyric attack, vigilance regarding signs and symptoms of an infection and/ or a porphyric attack is recommended.
Rationale
Antibody preparation with no CYP metabolism. Based on the pharmacokinetics, Anakinra is not expected to have any porphyrinogenic effects.
Chemical description
Human interleukin 1 receptor antagonist produced in Escherichia coli cells by recombinant DNA technology.
Therapeutic characteristics
Anakinra is used in the treatment of rheumatoid arthritis as monotherapy or in combination with methotrexate in patients with an inadequate response to methotrexate alone. It is administered as a subcutaneous injection.
Metabolism and pharmacokinetics
Anakinra is not metabolised by the liver via phase 1 mechanisms and is not known to inhibit cytochrome P450 enzymes. The metabolism of anakinra is expected to be similar as for endogenous antibodies, which are metabolised to peptides and amino acids in various body tissues and in plasma by circulating phagocytic cells or by their target antigen-containing cells.
References
- Drug reference publications
- Sweetman SC, editor. Martindale: The complete drug reference. Anakinra. Pharmaceutical Press 2009. #2314
- Government bodies
- European Public Assessment Report, Kineret (Scientific discussion).European Medicines Agency (EMEA). Accessible from: emea.europa.eu #2312
- Summary of Product Characteristics
- The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Kineret. (Last edition: November 2013). #2313
Similar drugs
© NAPOS 2024